UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 58

Sortiert nach

Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations

International journal of cancer, 2019-06, Vol.144 (11), p.2887-2896

2019

Volltextzugriff (PDF)

Is Real-World Evidence on Acquired Resistance to Osimertinib Relevant Clinically?

Journal of thoracic oncology, 2024-02, Vol.19 (2), p.187-189

Lee, Jih-Hsiang

2024

Volltextzugriff (PDF)

Factors associated with survival of patients with advanced lung cancer and long travel distances

Journal of the Formosan Medical Association, 2024-02, Vol.123 (2), p.273-282

2024

Volltextzugriff (PDF)

Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors

Proceedings of the National Academy of Sciences - PNAS, 2010-07, Vol.107 (29), p.13040-13045

2010

Volltextzugriff (PDF)

Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors

The oncologist (Dayton, Ohio), 2019-12, Vol.24 (12), p.e1417-e1425

2019

Volltextzugriff (PDF)

Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors

Journal of biomedical science, 2016-12, Vol.23 (1), p.86, Article 86

2016

Volltextzugriff (PDF)

A novel computer-assisted tool for 3D imaging of programmed death-ligand 1 expression in immunofluorescence-stained and optically cleared breast cancer specimens

BMC cancer, 2024-01, Vol.24 (1), p.121-121, Article 121

2024

Volltextzugriff (PDF)

Association of Programmed Death‐Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase‐Positive Lung Adenocarcinoma Receiving Crizotinib

The oncologist (Dayton, Ohio), 2020-08, Vol.25 (8), p.702-711

2020

Volltextzugriff (PDF)

Phase I, multicenter, open‐label, dose‐escalation study of sonidegib in Asian patients with advanced solid tumors

Cancer science, 2016-10, Vol.107 (10), p.1477-1483

2016

Volltextzugriff (PDF)

MicroRNA expression and clinical outcome of small cell lung cancer

PloS one, 2011-06, Vol.6 (6), p.e21300

2011

Volltextzugriff (PDF)

Enhancer of rudimentary homolog regulates DNA damage response in hepatocellular carcinoma

Scientific reports, 2015-04, Vol.5 (1), p.9357-9357, Article 9357

2015

Volltextzugriff (PDF)

Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells

Proceedings of the National Academy of Sciences - PNAS, 2012-12, Vol.109 (52), p.E3659-E3667

2012

Volltextzugriff (PDF)

Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer

Journal of thoracic oncology, 2014-04, Vol.9 (4), p.567-571

2014

Volltextzugriff (PDF)

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2014-09, Vol.9 (9), p.1385-1392

2014

Volltextzugriff (PDF)

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors

JTO clinical and research reports, 2022-11, Vol.3 (11), p.100405-100405, Article 100405

2022

Volltextzugriff (PDF)

Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer

Expert review of molecular diagnostics, 2016-12, Vol.16 (12), p.1251-1257

2016

Volltextzugriff (PDF)

Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma

Therapeutic advances in medical oncology, 2022, Vol.14, p.175883592211338-17588359221133889

2022

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis

Journal of thoracic oncology, 2015-12, Vol.10 (12), p.1754-1761

2015

Volltextzugriff (PDF)

Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors

Journal of the Formosan Medical Association, 2018-04, Vol.117 (4), p.326-331

2018

Volltextzugriff (PDF)

Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy

Lung cancer (Amsterdam, Netherlands), 2017-08, Vol.110, p.7-13

2017

Volltextzugriff (PDF)

Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors

European journal of cancer (1990), 2020-01, Vol.124, p.110-122

2020

Volltextzugriff (PDF)

High Prevalence of the BIM Deletion Polymorphism in Young Female Breast Cancer in an East Asian Country

PloS one, 2015-04, Vol.10 (4), p.e0124908

2015

Volltextzugriff (PDF)

Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC

JTO clinical and research reports, 2021-01, Vol.2 (1), p.100099-100099, Article 100099

2021

Volltextzugriff (PDF)

A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors

Investigational new drugs, 2020-02, Vol.38 (1), p.99-110

2020

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(55)

Publikationsform

Artikel
(58)

Sprache

Englisch
(58)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(41)
Life Sciences & Biomedicine
(36)
Humans
(31)
Oncology
(29)
Mutation
(18)
Female
(16)
Lung Neoplasms - Drug Therapy
(16)
Lung Neoplasms - Genetics
(15)
Male
(15)
Middle Aged
(13)
Aged
(12)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(12)
Protein Kinase Inhibitors - Therapeutic Use
(12)
Adult
(11)
Respiratory System
(11)
Tumors
(11)
Lung Cancer
(10)
Lung Neoplasms - Pathology
(10)
Non-Small Cell Lung Cancer
(10)
Carcinoma, Non-Small-Cell Lung - Genetics
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations

Is Real-World Evidence on Acquired Resistance to Osimertinib Relevant Clinically?

Factors associated with survival of patients with advanced lung cancer and long travel distances

Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors

Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors

Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors

A novel computer-assisted tool for 3D imaging of programmed death-ligand 1 expression in immunofluorescence-stained and optically cleared breast cancer specimens

Association of Programmed Death‐Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase‐Positive Lung Adenocarcinoma Receiving Crizotinib

Phase I, multicenter, open‐label, dose‐escalation study of sonidegib in Asian patients with advanced solid tumors

MicroRNA expression and clinical outcome of small cell lung cancer

Enhancer of rudimentary homolog regulates DNA damage response in hepatocellular carcinoma

Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells

Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small-Cell Lung Cancer

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors

Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer

Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis

A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer

Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors

Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy

Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors

High Prevalence of the BIM Deletion Polymorphism in Young Female Breast Cancer in an East Asian Country

Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC

A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors

Suchergebnisse filtern